GlassScriptPhysician profile
Godofredo M Rossi
NPI 1225073901
$24,346.96
in general payments reported to CMS, 2019-2025
75 companies · $3,982 in 2025
The $3,982 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,051 · 2020: $2,689 · 2021: $1,651 · 2022: $3,920 · 2023: $4,327 · 2024: $3,725 · 2025: $3,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $82.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,952.71 |
| Education | $82.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,947.37 | 2019-2025 | |
| Ucb, INC. | $1,576.02 | 2019-2025 | Nayzilam, Fintepla, Rystiggo |
| Sk Life Science, INC. | $1,554.28 | 2020-2025 | |
| Abbvie INC. | $1,254.55 | 2019-2025 | Qulipta, Ubrelvy, Duopa |
| Teva Pharmaceuticals USA, INC. | $1,057.85 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Eisai INC. | $1,022.79 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $937.32 | 2019-2025 | Nuplazid |
| Genzyme Corporation | $847.22 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $835.23 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbott Laboratories | $781.17 | 2019-2025 | Proclaim, Infinity, Eterna |
| Biogen, INC. | $669.35 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Argenx US, INC. | $657.91 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $653.87 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $580.60 | 2019-2025 | Ultomiris |
| Adamas Pharmaceuticals, INC. | $568.92 | 2019-2021 |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $548.71 | 2019-2022 | |
| Genentech USA, INC. | $532.21 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Supernus Pharmaceuticals, INC. | $490.21 | 2019-2025 | Qelbree |
| Medtronic, INC. | $465.02 | 2021-2025 | Activa PC, Percept PC Brainsense |
| Celgene Corporation | $459.64 | 2022-2025 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $398.00 | 2019-2025 | Fycompa |
| Scilex Pharmaceuticals INC. | $391.12 | 2019-2025 | Ztlido |
| Boston Scientific Corporation | $372.25 | 2019-2025 | General - Dbs, Vercise |
| Neurocrine Biosciences, INC. | $367.76 | 2022-2025 | Ingrezza, Ongentys |
| Sunovion Pharmaceuticals INC. | $278.21 | 2020-2022 | |
| Kyowa Kirin, INC. | $274.43 | 2019-2024 | Nourianz |
| Allergan, INC. | $253.00 | 2020 | |
| Lundbeck LLC | $240.63 | 2020-2025 | Rexulti |
| Corium, LLC | $232.63 | 2022-2023 | Adlarity |
| Amneal Pharmaceuticals LLC | $225.35 | 2019-2025 | Crexont, Rytary |
| Csl Behring | $223.41 | 2019-2023 | Hizentra |
| Novo Nordisk INC | $220.04 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $204.23 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $196.10 | 2022 | |
| Pfizer INC. | $185.08 | 2023-2025 | |
| Aucta Pharmaceuticals, INC. | $174.44 | 2024-2025 | Motpoly Xr |
| Janssen Biotech, INC. | $166.73 | 2025 | |
| Medtronic USA, INC. | $157.05 | 2019-2020 | |
| Acorda Therapeutics, INC | $142.02 | 2019-2024 | Inbrija |
| Collegium Pharmaceutical, INC. | $135.63 | 2022 | |
| Emd Serono, INC. | $134.53 | 2019-2021 | |
| Livanova USA, INC. | $130.81 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $127.42 | 2020-2025 | Valtoco |
| Assertio Therapeutics, INC. | $123.03 | 2019 | |
| Merck Sharp & Dohme LLC | $121.95 | 2022-2023 | Belsomra |
| Neuronetics, INC. | $119.56 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $110.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $91.14 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $89.43 | 2019 | |
| Ge Healthcare | $88.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $83.73 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $78.64 | 2024-2025 | |
| Averitas Pharma INC. | $69.05 | 2025 | Qutenza |
| Grt US Holding, INC. | $60.36 | 2022 | |
| Cycle Pharmaceuticals INC | $59.57 | 2024-2025 | Tascenso Odt |
| Avanir Pharmaceuticals, INC. | $55.63 | 2022 | |
| Vanda Pharmaceuticals INC. | $53.83 | 2025 | Ponvory |
| Mdd US Operations, LLC | $42.96 | 2019-2025 | Gocovri |
| Axsome Therapeutics, INC. | $36.05 | 2025 | Symbravo |
| Mallinckrodt Hospital Products INC. | $35.94 | 2020 | |
| Tersera Therapeutics LLC | $33.86 | 2019 | |
| Upsher-Smith Laboratories LLC | $33.38 | 2019-2020 | |
| Shire North American Group INC | $27.98 | 2019 | |
| Almatica Pharma LLC | $27.63 | 2021 | |
| Zyla Life Sciences, INC. | $27.58 | 2019 | |
| Aquestive Therapeutics, INC. | $26.98 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.82 | 2019-2023 | Trintellix |
| Arbor Pharmaceuticals, INC. | $25.80 | 2019-2020 | |
| Aprecia Pharmaceuticals, LLC | $24.38 | 2023 | Spritam |
| Life Molecular Imaging LTD | $22.28 | 2025 | Neuraceq |
| Idorsia Pharmaceuticals US INC | $21.94 | 2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $21.89 | 2025 | Givlaari |
| Tonix Medicines, INC. | $15.32 | 2025 | Tonmya |
| Impel Pharmaceuticals INC. | $13.28 | 2023 | Trudhesa |
| Insightec,INC | $8.38 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Godofredo Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.